Report prevalence phase results from the CATALYST trial
Delivered after the deadline (332 days after the deadline)
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 1 Nov 2023
- Due
- 31 Mar 2024
- Delivered
- 26 Feb 2025
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“prevalence phase results expected in first quarter of 2024”
What we found
Evidence strength A What the grades mean
The company did not report the full prevalence phase results by the Q1 2024 deadline; these results were first disclosed in the 10-K filed on February 26, 2025.
-
A Corcept Therapeutics Inc. 8-K filed 2024-05-01
“full prevalence phase results expected this quarter” ✓ confirmed on the page
-
A Corcept Therapeutics Inc. 10-K filed 2025-02-26
“In 2024, we conducted the CATALYST study to determine the prevalence of hypercortisolism... Of the 1,057 patients enrolled in the first phase of CATALYST, 23.8 percent were found to have hypercortisolism.” ✓ confirmed on the page
Market reaction: the shares moved -1.1% against the S&P 500 over the three sessions around the disclosure (25 Feb 2025 to 28 Feb 2025). What this measures
Checked 1 Oct 2026.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- Deadline drift +91 days
- 2 versions
-
Version 1 · original · stated 1 Nov 2023
Deadline 31 Mar 2024 (“first quarter of 2024”) · wording expected
-
Version 2 · stated 1 May 2024
Deadline 30 Jun 2024 (“this quarter”) · wording expected
“results from randomized withdrawal phase expected this quarter”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Report
- Deliverable
- CATALYST trial prevalence phase results
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: disagreesClaude (Anthropic) re-read the evidence blind and read it as “Not met”.
- Tie-breakA stronger model read the evidence and both earlier answers, without knowing which was recorded, and agrees with the recorded outcome.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Corcept Therapeutics Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2023-CORT-002884 · Corrections policy